GW Pharmaceuticals (GWP) - Notice of Results RNS Number : 7909R GW Pharmaceuticals PLC 22 November 2012 GW Pharmaceuticals plc Notification of Results Porton Down,UK;22November 2012:GW Pharmaceuticals plc (AIM: GWP) will be announcing its Preliminary financial results for the year ended 30 September 2012, on Wednesday 28 November 2012. -ends- Enquiries: FTI Consulting + 44 20 7831 3113 Ben Atwell / John Dineen / Simon Conway Notes to Editors About GW GW was founded in 1998 and listed on the AIM, a market of the London Stock Exchange, in June 2001. Operating under license from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular multiple sclerosis and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. For further information, please visit www.gwpharm.com This information is provided by RNS The company news service from the London Stock Exchange END NORFLLFLLFFLFBK -0- Nov/22/2012 11:31 GMT
GW Pharmaceuticals GWP Notice of Results
Press spacebar to pause and continue. Press esc to stop.